Add to ORKGApproximately 20 % of all Hodgkin lym-phoma (HL) patients are older than 60 years and have a poor prognosis, mainly because of increased treatment-related toxicity resulting in reduced over-all dose intensity and more treatment-related mortality. To possibly improve the treatment of elderly HL patients, the Ger-man Hodgkin Study Group developed a new regimen, PVAG (prednisone, vinblas-tine, doxorubicin, and gemcitabine). In this multicenter phase 2 study, elderly HL patients in early unfavorable and ad-vanced stages received 6 to 8 cycles of PVAG and additional radiotherapy if the
Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, pro...
There is a lack of contemporary prospective data examining the adriamycin, bleomycin, vinblastine, d...
Classical Hodgkin's lymphoma (cHL) is a rather rare disease with an incidence of 2-3/100,000 per yea...
Approximately 20% of all Hodgkin lymphoma (HL) patients are older than 60 years and have a poor prog...
In advanced age the prognosis of Hodgkin's lymphoma (HL) is poor, but, as a consequence of the low i...
Background: In advanced age the prognosis of Hodgkin’s lymphoma (HL) is poor, but, as a consequence ...
Hodgkin Lymphoma HL ica be cured in the large majority of younger patients, but prognosis for o...
The outcome of patients with Hodgkin lymphoma (HL) has dramatically improved over the past decades a...
For older patients with early unfavorable or advanced stage Hodgkin lymphoma (HL) the prognosis is m...
Survival rates for elderly Hodgkin Lymphoma (HL) have not improved substantially in recent years, ma...
About 30% of all Hodgkin lymphoma (HL) patients are >= 60 years old. As lenalidomide has promising s...
Phase II study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderl
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However,...
In the Swedish National Care Programme for Hodgkin's lymphoma (HL) a less intensive chemotherapy reg...
In the past decades, Hodgkin lymphoma (HL) has turned from an incurable disease to one with the most...
Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, pro...
There is a lack of contemporary prospective data examining the adriamycin, bleomycin, vinblastine, d...
Classical Hodgkin's lymphoma (cHL) is a rather rare disease with an incidence of 2-3/100,000 per yea...
Approximately 20% of all Hodgkin lymphoma (HL) patients are older than 60 years and have a poor prog...
In advanced age the prognosis of Hodgkin's lymphoma (HL) is poor, but, as a consequence of the low i...
Background: In advanced age the prognosis of Hodgkin’s lymphoma (HL) is poor, but, as a consequence ...
Hodgkin Lymphoma HL ica be cured in the large majority of younger patients, but prognosis for o...
The outcome of patients with Hodgkin lymphoma (HL) has dramatically improved over the past decades a...
For older patients with early unfavorable or advanced stage Hodgkin lymphoma (HL) the prognosis is m...
Survival rates for elderly Hodgkin Lymphoma (HL) have not improved substantially in recent years, ma...
About 30% of all Hodgkin lymphoma (HL) patients are >= 60 years old. As lenalidomide has promising s...
Phase II study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderl
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However,...
In the Swedish National Care Programme for Hodgkin's lymphoma (HL) a less intensive chemotherapy reg...
In the past decades, Hodgkin lymphoma (HL) has turned from an incurable disease to one with the most...
Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, pro...
There is a lack of contemporary prospective data examining the adriamycin, bleomycin, vinblastine, d...
Classical Hodgkin's lymphoma (cHL) is a rather rare disease with an incidence of 2-3/100,000 per yea...